Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia

- More than 3 million people in the US have severe hypertriglyceridemia - The CORE Phase 3 clinical study further expands Ionis' late-stage pipeline and is the second Phase 3 clinical study in Ionis' broad olezarsen development program - Olezarsen is one of Ionis' wholly owned medicines the company plans to commercialize CARLSBAD, Calif., Nov. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx. The CORE study is evaluating olezarsen in people with severe hypertriglyceridemia (triglyceride levels ≥ 500 mg/dL). Severe hypertriglyceridemia is a life-threatening condition associated with high levels of apoC-III and chylomicronemia, which lead to higher rates of acute pancreatitis, higher risk of cardiovascular disease, and has a high morbidity rate.

The release as fetched from its publisher. ionis.com ↗